ReviewInternational urology and nephrology2002
Diabetic nephropathy-pathophysiology and management.
Review in International urology and nephrology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- MGAT5 regulates ferroptosis via the Nrf2/HO-1 signaling pathway in diabetic nephropathy.Open life sciences · 2026Article
- Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.American journal of physiology. Renal physiology · 2020Article
- Correlation between Diabetes Mellitus and Knee Osteoarthritis: A Dry-To-Wet Lab Approach.International journal of molecular sciences · 2018Article
- Adult chronic kidney disease: neurocognition in chronic renal failure.Neuropsychology review · 2010Review
- Does glomerular hyperfiltration in pregnancy damage the kidney in women with more parities?International urology and nephrology · 2009Article
- Unexplained anemia in the elderly.Seminars in hematology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is the leading cause of end-stage renal disease in the United States. Between 1996 and 2001, the prevalence of diabetes in the Medicare population increased by 319%. Patients with diabetes account for approximately one-third of all cases of end-stage renal disease (ESRD). This number is expected to rise dramatically as a result of the growing incidence of diabetes and the aging population. A major complication of diabetes includes end-stage renal disease as a result from diabetic nephropathy. The earliest clinical evidence that nephropathy exists is the appearance of low, yet abnormal, levels of albumin in the urine, referred to as microalbuminuria. This can progress to proteinuria representing overt diabetic nephropathy. Prevention remains the best way to reduce mortality and maintain a high quality of life in these individuals as recent clinical trials confirm that it is possible to not only slow down the progression of diabetic nephropathy, but even prevent it from becoming a significant problem. This article reviews the pathogenesis, diagnostic screening, and treatment strategies of diabetic nephropathy.
Indexed as
Identifiers
12775108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.